| アブストラクト | IMPORTANCE: The use of dipeptidyl-peptidase-4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues-a group of drugs used in the management of type 2 diabetes mellitus-may be associated with an increased risk of bile duct and gallbladder disease. To date, no observational study has assessed this possible association. OBJECTIVE: To determine whether the use of DPP-4 inhibitors and GLP-1 analogues is associated with an increased risk of incident bile duct and gallbladder disease in patients with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study linked the United Kingdom Clinical Practice Research Datalink with the Hospital Episodes Statistics database, yielding a cohort of 71369 patients, 18 years or older, initiating an antidiabetic drug (including oral and injectable agents) between January 1, 2007, and March 31, 2014. EXPOSURES: Current use of DPP-4 inhibitors and GLP-1 analogues (alone or in combination therapy) compared with current use of at least 2 oral antidiabetic drugs. MAIN OUTCOMES AND MEASURES: Time-dependent Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% CIs of incident bile duct or gallbladder events (cholelithiasis, cholecystitis, cholangitis) causing hospitalization, comparing current use of DPP-4 inhibitors and GLP-1 analogues with current use of at least 2 oral antidiabetic drugs. RESULTS: During 227994 person-years of follow-up, 853 of the 71369 patients were hospitalized for bile duct and gallbladder disease (incidence rate per 1000 person-years, 3.7; 95% CI, 3.5-4.0). Current use of DPP-4 inhibitors was not associated with an increased risk of bile duct and gallbladder disease compared with current use of at least 2 oral antidiabetic drugs (3.6 vs 3.3 per 1000 person-years; adjusted HR, 0.99; 95% CI, 0.75-1.32). In contrast, the use of GLP-1 analogues was associated with an increased risk of bile duct and gallbladder disease compared with current use of at least 2 oral antidiabetic drugs (6.1 vs 3.3 per 1000 person-years; adjusted HR, 1.79; 95% CI, 1.21-2.67). In a secondary analysis, GLP-1 analogues were also associated with an increased risk of cholecystectomy (adjusted HR, 2.08; 95% CI, 1.08-4.02). CONCLUSIONS AND RELEVANCE: The use of GLP-1 analogues was associated with an increased risk of bile duct and gallbladder disease. Physicians should be aware of this potential adverse event when prescribing these drugs. |
|---|
| 組織名 | Laboratory of Biostatistics, Epidemiology, and Public Health (Equipe d'Acceuil;2415), Faculty of Medicine, University of Montpellier, Montpellier,;France2Department of Medical Pharmacology and Toxicology, Montpellier University;Hospital, Montpellier, France.;Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital,;Montreal, Quebec, Canada4Division of Endocrinology, Jewish General Hospital,;Montreal, Quebec, Canada.;Department of Medical Pharmacology and Toxicology, Montpellier University;Hospital, Montpellier, France5Institut National de la Sante et de la Recherche;Medicale (INSERM), Unite 1058, Faculty of Medicine, University Montpellier 1,;Montpellier, France.;Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec,;Canada.;Montreal, Quebec, Canada7Department of Oncology, McGill University, Montreal,;Quebec, Canada. |
|---|
